International Journal of Medical Sciences

Impact factor
2.399

20 October 2017

ISSN 1449-1907 News feeds of published articles

My Manuscript | My Account

Journal of Genomics now in PubMed/PubMed Central. Submit manuscript...

Journal of Biomedicinenew

Theranostics

Journal of Cancer

Oncomedicine

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2013; 10(8):988-994. doi:10.7150/ijms.5944

Research Paper

Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis

Jiunn-Min Shieh1,2, Yen-An Tang3, Tsung-Han Yang3, Chih-Yi Chen4, Han-Shui Hsu5, Yi-Hung Carol Tan3, Ravi Salgia6, Yi-Ching Wang3 ✉

1. Department of Chest Medicine, Chi Mei Medical Center, Tainan, Taiwan, R.O.C.;
2. Chang Jung Christian University;
3. Department of Pharmacology and Institute of Basic Medical Science, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R. O. C.;
4. Cancer Center, China Medical University Hospital, Taichung, Taiwan, R. O. C.;
5. Institute of Emergency and Critical Care Medicine, National Yang Ming University, Division of Thoracic Surgery, Taipei Veterans General Hospital, Taiwan, R. O. C.;
6. Departments of Medicine, University of Chicago Medical Center, Chicago, USA.

Abstract

Background: Previously, we identified a sequence variant (N375S) of c-Met gene, however, its association with lung cancer risk and prognosis remain undefined.

Patients and Methods: We investigated the genotype distribution of the c-Met-N375S sequence variant in 206 lung cancer patients and 207 non-cancer controls in the Taiwanese population by DNA sequencing.

Results: Lung cancer patients with variant A/G and G/G genotypes showed 1.08-fold increased cancer risk when compared to patients with the wild-type A/A genotype (95% CI, 0.60-1.91). There were no significant differences in postoperative survival between c-Met-N375S and wild-type patients. In the cell model, the c-Met-N375S cells showed a decrease in cell death upon treatment with MET inhibitor SU11274 compared to wild-type cells.

Conclusion: Our data suggest that the c-Met-N375S sequence variant may not play a significant role in cancer susceptibility and the prognosis of lung cancer patients. The correlation with chemoresponse of c-Met-N375S is worth further investigation in patients receiving MET therapy.

Keywords: c-Met, N375S, cancer risk, prognosis, lung cancer.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Shieh JM, Tang YA, Yang TH, Chen CY, Hsu HS, Tan YHC, Salgia R, Wang YC. Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis. Int J Med Sci 2013; 10(8):988-994. doi:10.7150/ijms.5944. Available from http://www.medsci.org/v10p0988.htm